Compare SCYX & LVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCYX | LVO |
|---|---|---|
| Founded | 1999 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.4M | 45.5M |
| IPO Year | 2014 | 2010 |
| Metric | SCYX | LVO |
|---|---|---|
| Price | $5.05 | $2.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $36.33 | $9.75 |
| AVG Volume (30 Days) | ★ 259.2K | 112.7K |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.36 | ★ 78.57 |
| EPS | N/A | ★ N/A |
| Revenue | $257,000.00 | ★ $77,144,000.00 |
| Revenue This Year | N/A | $6.07 |
| Revenue Next Year | $906.41 | $27.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.57 | $2.24 |
| 52 Week High | $6.09 | $7.19 |
| Indicator | SCYX | LVO |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 37.30 |
| Support Level | $4.65 | N/A |
| Resistance Level | $5.44 | $5.83 |
| Average True Range (ATR) | 0.43 | 0.31 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 68.31 | 26.71 |
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
LiveOne Inc creator-first, music, entertainment and technology platform focused on delivering premium experiences and content world-wide through paid users and live and virtual events. It is in the acquisition, distribution and monetization of live music events, Internet radio, podcasting/vodcasting and music-related membership, streaming and video content. It provide services through a dedicated over-the-top application powered by Slacker (LiveOne App) called LiveOne. The company has three operating segments, PodcastOne, Slacker and Media Group. The company generates majority of revenue from PodcastOne. Its operations are based in the United States. It generate revenue through the sale of paid user services and advertising from its music offerings, from the licensing, advertising.